##### Table of Contents



SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
 
 Form 10-Q/A þ
    
    QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the quarterly period
ended   March 31, 2005 o
    
    TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period fromto Commission File No.: 0-51149 Emageon Inc. 
 (Exact name of registrant as specified in its charter)
 Delaware
    
    63-1240138(State of incorporation)
    
    (I.R.S. Employer Identification No.)1200 Corporate Drive, Suite 200Birmingham, Alabama
    
    35242(Address of principal executive offices)
    
    (zip code)
 Registrants telephone number, including area code:(205) 980-9222   Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. YES þ NO o Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange
Act Rule 12b-2). YES o NO þ The number of shares outstanding of the registrants Common Stock, par value $.001 per share,
as of May 9, 2005 was 20,027,621.




---



##### Table of Contents



EXPLANATORY NOTE: This
Amendment No. 1 supersedes and restates in its entirety our quarterly
report on Form 10-Q for the period ended March 31, 2005
originally filed on May 16, 2005. The purpose of this Amendment
No. 1 is to delete the last sentence of the third paragraph under
the subheading Cost of Revenue contained within
Item 2 Managements Discussion and Analysis of Financial
Condition and Results of Operations relating to an expected
accelerated depreciation charge. It is anticipated that this accelerated depreciation will
occur in one or more subsequent quarters.




---



TABLE OF CONTENTS PagePART I: FINANCIAL INFORMATIONItem 1: Financial Statements
    
    
    1Item 2: Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    8Item 3: Quantitative and Qualitative Disclosures About Market Risk
    
    
    18Item 4: Controls and Procedures
    
    
    19PART II: OTHER INFORMATIONItem 1: Legal Proceedings
    
    
    19Item 2: Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    19Item 4: Submission of Matters to a Vote of Security Holders
    
    
    20Item 6: Exhibits
    
    
    21SIGNATURES
    
    
    23EX-31.1 SECTION 302, CERTIFICATION OF THE CEOEX-31.2 SECTION 302, CERTIFICATION OF THE CFOEX-32.1 SECTION 906, CERTIFICATION OF THE CEO AND CFO
  2




---



##### Table of Contents



PART I: FINANCIAL INFORMATION 
 ITEM 1: FINANCIAL STATEMENTS EMAGEON INC. CONSOLIDATED BALANCE SHEETS March 31,
    
    
    December 31,2005
    
    
    2004(Unaudited)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    40,614,285
    
    
    $
    5,994,589Marketable securities
    
    
    29,582,046
    
    
    
    Trade accounts receivable, net of allowance for doubtful accounts of $75,000
    
    
    10,871,042
    
    
    
    14,255,375Prepaid expenses and other current assets
    
    
    1,953,029
    
    
    
    1,799,046Deferred offering costs
    
    
    
    
    
    
    1,326,242Unbilled revenue
    
    
    264,495
    
    
    
    301,584Third-party components to be sold to customers
    
    
    1,412,761
    
    
    
    1,421,887Total current assets
    
    
    84,697,658
    
    
    
    25,098,723Property and equipment, net
    
    
    10,394,517
    
    
    
    8,832,113Restricted cash
    
    
    530,494
    
    
    
    902,997Other noncurrent assets
    
    
    115,859
    
    
    
    61,859Intangible assets:Goodwill
    
    
    3,754,586
    
    
    
    3,754,586Acquired software, net
    
    
    2,638,660
    
    
    
    2,846,977Capitalized software development costs, net
    
    
    103,274
    
    
    
    20,726Trademark
    
    
    250,000
    
    
    
    250,0006,746,520
    
    
    
    6,872,289Total assets
    
    $
    102,485,048
    
    
    $
    41,767,981LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS EQUITY (DEFICIT)Current liabilities:Accounts payable
    
    $
    7,041,793
    
    
    $
    4,657,906Accrued payroll and related costs
    
    
    937,163
    
    
    
    1,557,566Deferred revenue
    
    
    22,736,551
    
    
    
    21,357,609Other accrued expenses
    
    
    1,669,713
    
    
    
    3,837,841Current portion of long-term debt
    
    
    1,896,489
    
    
    
    2,471,759Current portion of capital lease obligations
    
    
    634,718
    
    
    
    619,666Total current liabilities
    
    
    34,916,427
    
    
    
    34,502,347Long-term deferred revenue
    
    
    2,927,558
    
    
    
    2,795,738Deferred tax liability
    
    
    95,000
    
    
    
    95,000Long-term debt
    
    
    2,283,499
    
    
    
    5,527,960Capital lease obligations, less current portion
    
    
    704,014
    
    
    
    868,686Total liabilities
    
    
    40,926,498
    
    
    
    43,789,731Redeemable preferred stock:Series B redeemable preferred stock, $0.001 par value; 17,200,000 shares
authorized, no shares and 16,885,966 shares issued and outstanding at March
31, 2005 and December 31, 2004, respectively
    
    
    
    
    
    
    9,597,550Series B-1 redeemable preferred stock, $0.001 par value; 5,700,000 shares
authorized, no shares and 5,652,631 shares issued and outstanding at March
31, 2005 and December 31, 2004, respectively
    
    
    
    
    
    
    3,209,801Series C redeemable preferred stock, $0.001 par value; 27,500,000 shares
authorized, no shares and 27,433,370 shares issued and outstanding at March
31, 2005 and December 31, 2004, respectively
    
    
    
    
    
    
    11,620,280Series E redeemable preferred stock, $0.001 par value; 14,050,000 shares
authorized, no shares and 14,035,087 shares issued and outstanding at March
31, 2005 and December 31, 2004, respectively
    
    
    
    
    
    
    5,920,761Total redeemable preferred stock
    
    
    
    
    
    
    30,348,392Stockholders equity (deficit):Series A preferred stock, $0.001 par value; 5,965,000 shares authorized, no
shares and 5,965,000 shares issued and outstanding at March 31, 2005 and
December 31, 2004, respectively
    
    
    
    
    
    
    1,438,543Series D preferred stock, $0.001 par value; 18,000,000 shares authorized, no
shares and 13,727,358 shares issued and no shares and 12,354,620 outstanding
at March 31, 2005 and December 31, 2004, respectively
    
    
    
    
    
    
    5,868,446Common stock, $0.001 par value; 66,000,000 and 165,050,000 shares authorized,
20,203,378 and 3,056,181 issued and 20,027,621 and 2,709,370 shares outstanding
at March 31, 2005 and December 31, 2004, respectively
    
    
    20,203
    
    
    
    3,056Additional paid in capital
    
    
    113,042,683
    
    
    
    6,997,757Treasury stock, 175,757 shares, at cost
    
    
    (275,500
    )
    
    
    (275,500
    )Accumulated deficit
    
    
    (51,228,836
    )
    
    
    (46,402,444
    )Total stockholders equity (deficit)
    
    
    61,558,550
    
    
    
    (32,370,142
    )Total liabilities, redeemable preferred stock and stockholders equity (deficit)
    
    $
    102,485,048
    
    
    $
    41,767,981
 The accompanying Notes to Consolidated Financial Statements are an integral part of these statements. 1




---



##### Table of Contents



EMAGEON INC. CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited) For the Three Months EndedMarch 31,2005
    
    
    2004Revenue:System sales
    
    $
    7,719,033
    
    
    $
    4,909,043Support services
    
    
    3,617,289
    
    
    
    2,208,025Total revenue
    
    
    11,336,322
    
    
    
    7,117,068Cost of revenue:System sales
    
    
    4,823,021
    
    
    
    3,489,291Support services
    
    
    3,083,346
    
    
    
    2,279,070Total cost of revenue
    
    
    7,906,367
    
    
    
    5,768,361Gross profit
    
    
    3,429,955
    
    
    
    1,348,707Operating expenses:Research and development
    
    
    2,384,728
    
    
    
    1,269,043Sales and marketing
    
    
    2,689,483
    
    
    
    1,737,592General and administrative
    
    
    2,555,199
    
    
    
    1,741,767Total operating expenses
    
    
    7,629,410
    
    
    
    4,748,402Operating loss
    
    
    (4,199,455
    )
    
    
    (3,399,695
    )Other income (expense):Interest income
    
    
    232,788
    
    
    
    1,499Interest expense
    
    
    (851,425
    )
    
    
    (193,832
    )Total other income (expense)
    
    
    (618,637
    )
    
    
    (192,333
    )Net loss
    
    $
    (4,818,092
    )
    
    $
    (3,592,028
    )Net loss per share -basic and diluted
    
    $
    (0.42
    )
    
    $
    (1.48
    )Weighted average common stock outstanding -basic and diluted
    
    
    11,531,986
    
    
    
    2,430,648
 The accompanying Notes to Consolidated Financial Statements are an integral part of these statements. 2




---



##### Table of Contents



EMAGEON INC. CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited) For the Three Months EndedMarch 31,2005
    
    
    2004Operating activitiesNet loss
    
    $
    (4,818,092
    )
    
    $
    (3,592,028
    )Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation
    
    
    543,961
    
    
    
    324,093Depreciation of property and equipment at contracted customer sites
    
    
    607,142
    
    
    
    706,741Amortization of acquired software
    
    
    208,317
    
    
    
    208,316Amortization of capitalized software development costs
    
    
    5,625
    
    
    
    88,910Interest income on restricted cash
    
    
    (1,634
    )
    
    
    (1,393
    )Sales discount from issuance of warrants
    
    
    30,801
    
    
    
    Consulting expense for options issued to non-employees
    
    
    40,320
    
    
    
    Amortization and write off of subordinated debt discount
    
    
    645,893
    
    
    
    Stock based compensation expense
    
    
    281,988
    
    
    
    59,206Changes in operating assets and liabilities:Trade accounts receivable
    
    
    3,384,333
    
    
    
    (1,556,040
    )Prepaid expenses and other current assets
    
    
    (184,784
    )
    
    
    (472,184
    )Unbilled revenue
    
    
    37,089
    
    
    
    (3,207
    )Other noncurrent assets
    
    
    (54,000
    )
    
    
    Third-party components to be sold to customers
    
    
    9,126
    
    
    
    (529,112
    )Accounts payable
    
    
    2,383,887
    
    
    
    1,106,620Accrued payroll and related costs
    
    
    (620,403
    )
    
    
    (318,879
    )Other accrued expenses
    
    
    (2,168,128
    )
    
    
    834,626Deferred revenue
    
    
    1,510,762
    
    
    
    3,503,934Net cash provided by operating activities
    
    
    1,842,203
    
    
    
    359,603Investing activitiesPurchases of property and equipment for internal purposes
    
    
    (1,972,357
    )
    
    
    (285,753
    )Purchases of third-party components to be located at contracted customer sites
    
    
    (741,150
    )
    
    
    (61,139
    )Purchases of marketable securities
    
    
    (29,582,046
    )
    
    
    Capitalized software development costs
    
    
    (88,173
    )
    
    
    Net cash used in investing activities
    
    
    (32,383,726
    )
    
    
    (346,892
    )Financing activitiesProceeds from issuance of common stock, net of issuance costs
    
    
    69,348,735
    
    
    
    4,261Proceeds from issuance of preferred stock, net of issuance costs
    
    
    53,591
    
    
    
    Payments on capital lease obligations
    
    
    (149,620
    )
    
    
    (114,040
    )Payments of loans
    
    
    (4,465,624
    )
    
    
    (445,741
    )Additions to restricted cash to secure letter of credit
    
    
    
    
    
    
    (96,000
    )Cash released from restriction
    
    
    374,137
    
    
    
    Net cash provided by (used in) financing activities
    
    
    65,161,219
    
    
    
    (651,520
    )Net increase (decrease) in
cash and cash equivalents
    
    
    34,619,696
    
    
    
    (638,809
    )Cash and
cash equivalents at beginning of period
    
    
    5,994,589
    
    
    
    2,340,407Cash and
cash equivalents at end of period
    
    $
    40,614,285
    
    
    $
    1,701,598
 The accompanying Notes to Consolidated Financial Statements are an integral part of these statements. 3




---



##### Table of Contents



EMAGEON INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED) (1) BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited condensed consolidated financial statements of Emageon Inc.
(Emageon or the Company) have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01
of Regulation S-X. Accordingly, they do not include all of the information and notes required by
accounting principles generally accepted in the United States of America. In the opinion of
management, all adjustments, consisting only of normal recurring adjustments, for a fair
presentation have been included. Operating results for the three months ended March 31, 2005 are
not necessarily indicative of the results that may be expected for the year ending December 31,
2005. These financial statements should be read in conjunction with the financial statements and
notes thereto included in the Companys Annual Report on Form 10-K for the year ended December 31,
2004. Certain amounts in the prior period financial statements have been reclassified to conform
to the current financial statement presentation. Securities Held-to-Maturity The Company is required to classify debt securities as held-to-maturity, available-for-sale or
trading. The appropriateness of each classification is reassessed at each reporting date. As of
March 31, 2005, the Company classified all debt securities as held-to-maturity. At March 31, 2005,
securities held-to-maturity totaling $29,582,046 consisted of U.S. Government Agency securities as
well as marketable debt securities carried at amortized cost in accordance with the Financial
Accounting Standards Board Statement No. 115, Accounting for Certain Investments in Debt and
Equity Securities. The estimated fair value of all held-to-maturity securities at March 31, 2005
was approximately $29,609,900. Income Taxes The Company accounts for income taxes using the asset and liability method. Deferred income
tax assets and liabilities are determined based on differences between financial reporting and tax
bases of assets and liabilities and are measured using the enacted tax rates and laws that will be
in effect when the differences are expected to reverse. Valuation allowances are established when
necessary to reduce deferred tax assets to the amounts expected to be realized. The Company has
established a full valuation allowance against its deferred tax assets. Indemnification Provisions In November 2002, the FASB issued Financial Interpretation No. 45, Guarantors Accounting and
Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others
(FIN 45), which is an interpretation of SFAS Nos. 5, 57, and 107 and rescission of FASB
Interpretation No. 34. FIN 45 requires that a guarantor recognize, at the inception of a
guarantee, a liability for the fair value of the obligation undertaken by issuing the guarantee.
FIN 45 also requires additional disclosures to be made by a guarantor in its interim and annual
financial statements about its obligations under certain guarantees it has issued. The accounting
requirements for the initial recognition of guarantees are applicable on a prospective basis for
guarantees issued or modified after December 31, 2002. The following is a summary of those of our
agreements that we have determined to be within the scope of FIN 45: (1) Our sales agreements with customers generally contain infringement indemnity provisions.
Under these agreements, we agree to indemnify, defend and hold harmless the customer in connection
with patent, copyright or trade secret infringement claims made by third parties with respect to
the customers authorized use of our products and services. The indemnity provisions generally
provide for our control of any required defense and settlement and cover costs and damages finally
awarded against the customer. Our infringement indemnity provisions typically give us the option
to make modifications of the product so it is no longer infringing or, if it cannot be corrected,
to require the customer to return the product in exchange for a specified payment for loss of use.
Our sales agreements 4




---



##### Table of Contents



with customers sometimes also contain indemnity provisions for death, personal injury or
property damage caused by our personnel or contractors in the course of performing services to
customers. Under these agreements, we agree to indemnify, defend and hold harmless the customer in
connection with death, personal injury and property damage claims made by third parties with
respect to actions of our personnel or contractors. The indemnity provisions generally provide for
our control of any required defense and settlement and cover costs and damages finally awarded
against the customer. The indemnity obligations contained in sales agreements generally have no
specified expiration date but typically limit the amount of award covered to some portion of the
fees paid by the customer over some portion of the contract term. To date, we have not incurred
costs to settle claims or pay awards under these indemnification obligations. Accordingly, we have
no liabilities recorded for these provisions as of March 31, 2005. (2) We warrant that our software products will perform in all material respects in accordance
with our standard published specifications in effect at the time of delivery of the licensed
products to the customer as long as the contract remains in effect. Additionally, we warrant that
our services will be performed by qualified personnel in a manner consistent with normally accepted
industry standards. If necessary, we would provide for the estimated cost of product and service
warranties based on specific warranty claims and claim history. However, we have not incurred
significant recurring expense under our product or service warranties. Accordingly, we have no
liabilities recorded for these provisions as of March 31, 2005. (3) Our standard contracts with customers typically provide for a 99% guarantee of system
availability and a 98% guarantee of component availability with penalty provisions if our solution
fails to meet the guarantee thresholds. Our 99% system availability guarantee covers our solution
as a whole, while the component guarantee covers each individual component, as in certain
circumstances a component may fail without affecting system availability. The penalty provisions
in our contracts typically allow for a reduction in the software maintenance fee related to failure
to meet guaranteed uptime percentages. We calculate these penalties as a percentage of the
software maintenance fee and would reduce the amount of the software maintenance fee charged in a
specific period for these penalties. To date, we have not incurred any penalties associated with
these guarantees. Accordingly, we have no liabilities recorded for these provisions as of March
31, 2005. (2) COMPUTATION OF NET LOSS PER SHARE Net loss per share  basic is computed using the weighted average common shares outstanding
during the period. Net loss per share -diluted is computed using the weighted average common
shares outstanding and common share equivalents shares outstanding during the period. Common share
equivalents consist of common convertible preferred stock, stock warrants and options to purchase
common stock. Certain potential dilutive shares of common stock were excluded from periods with a
net loss because they were anti-dilutive. 5




---



##### Table of Contents



The computations for basic and diluted net loss per share for each period are as follows: Three Months EndedMarch 31,2005
    
    
    2004Numerator:Net loss
    
    $
    (4,818,092
    )
    
    $
    (3,592,028
    )Accretion of redemption value related to
redeemable preferred stock
    
    
    (8,300
    )
    
    
    (16,599
    )Net loss allocable to common stockholders
    
    $
    (4,826,392
    )
    
    $
    (3,608,627
    )Denominator:Common stock outstanding at beginning of period
    
    
    2,709,370
    
    
    
    2,429,742Weighted average effect of the conversion of
preferred stock to common stock
    
    
    5,542,188
    
    
    
    Weighted average effect of the issuance of
common stock in initial public offering
    
    
    2,905,556
    
    
    
    Weighted average effect of the issuance of
common stock and preferred stock pursuant to
stock option and warrant exercises
    
    
    287,447
    
    
    
    906Weighted average effect of the release of
escrowed common stock upon completion of
initial public offering
    
    
    87,425
    
    
    
    Weighted average number of shares of common stock-basic and diluted
    
    
    11,531,986
    
    
    
    2,430,648Net loss per share-basic and diluted
    
    $
    (0.42
    )
    
    $
    (1.48
    )
 Preferred stock convertible into 10,827,403 shares of common stock for the three months ended
March 31, 2004 was not included in the computation of diluted earnings per share because the effect
on earnings per share would have been anti-dilutive. Options and warrants to purchase 2,400,388 and
3,340,888 shares of common stock for the three month periods ended March 31, 2005 and 2004,
respectively, and warrants to purchase none and 216,138 shares of Series D preferred stock for the
three month periods ended March 31, 2005 and 2004, respectively, were not included in the
computation of diluted earnings per share because their effect on earnings per share would have
been anti-dilutive. (3) STOCK-BASED COMPENSATION The Company recognizes compensation expense for its stock-based employee and director
compensation plans using the intrinsic value method prescribed in Accounting Principles Board
Opinion (APB) No. 25, Accounting for Stock Issued to Employees(APB 25), and complies with the
disclosure provisions of SFAS No. 123, Accounting for Stock-Based Compensation,as amended. Under
APB 25, compensation expense of fixed stock options is based on the difference, if any, on the date
of the grant between the fair value of the stock and the exercise price of the option.
Compensation expense is recognized on a straight-line basis over the vesting period, which is
generally three years. The Company recognizes expense for stock-based compensation issued to
non-employees and non-directors at fair value in accordance with the provisions of SFAS No. 123 and
EITF Issue No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for
Acquiring, or in Conjunction with Selling, Goods or Services. Had compensation expense for the stock-based compensation plans been determined using the
fair-value method at the grant date for all employee and director awards using the Black-Scholes
pricing model, the net loss and related net loss per share would have been as follows for the
periods indicated: 6




---



##### Table of Contents



Three Months EndedMarch 31,2005
    
    
    2004Numerator:Actual net loss
    
    $
    (4,818,092
    )
    
    $
    (3,592,028
    )Deduct: Accretion of redemption value related
to redeemable preferred stock
    
    
    (8,300
    )
    
    
    (16,599
    )Add: Total stock-based employee compensation
expense determined under APB 25
    
    
    281,988
    
    
    
    59,206Deduct: Total stock-based employee
compensation expense determined under fair
value method for all awards
    
    
    (526,022
    )
    
    
    (73,866
    )Pro forma net loss allocable to common stockholders
    
    $
    (5,070,426
    )
    
    $
    (3,623,287
    )Denominator:Weighted average number of shares of common
stock-basic and diluted
    
    
    11,531,986
    
    
    
    2,430,648Pro forma net loss per share -basic and diluted
    
    $
    (0.44
    )
    
    $
    (1.49
    )
 The pro forma effects on the net loss for the periods presented above are not necessarily
representative of the pro forma effects that may occur in future periods. (4) INITIAL PUBLIC OFFERING On February 14, 2005, the Company completed the initial public offering of its common stock.
The Company sold 5,000,000 shares of its common stock at a price of $13.00 per share. On February
18, 2005, the over-allotment option to purchase 750,000 additional shares of common stock was
exercised at $13.00 per share. Total proceeds from the initial public offering (net of
underwriting discount and offering expenses) were approximately $67.2 million. In conjunction with
the initial public offering, the Company issued 10,827,403 shares of common stock upon the
automatic conversion of outstanding shares of preferred stock into shares of common stock. The
Company also issued 537,082 shares of common stock upon the required exercise of warrants to
purchase common stock upon the closing of the offering. The Company also released the remaining
escrow holdback related to the Ultravisual Medical Systems Corporation (Ultravisual) merger upon
the closing of the offering. Upon completion of the offering, 552,661 of common stock warrants
with an exercise price of $0.00825 per share were canceled. As of the close of the initial public
offering, the Company had no remaining warrants to purchase preferred stock outstanding. With a portion of the proceeds from the offering, the Company repaid $4.0 million of its
subordinated debt on February 18, 2005. Concurrent with this repayment, the Company recorded a
non-cash interest charge of $621,012 for the write-off of the debt discount related to warrants
issued in connection with the subordinated debt. (5) NEW ACCOUNTING PRONOUNCEMENT In December 2004, the Financial Accounting Standards Board issued Statement No. 123 (revised
2004), Share-Based Payment (SFAS 123R). SFAS 123R establishes standards for the accounting for
transactions in which an entity exchanges its equity instruments for goods or services. It focuses
primarily on accounting for transactions in which an entity obtains employee services in
share-based payment transactions. SFAS 123R requires a public entity to measure the cost of
employee services received in exchange for an award of equity instruments based on the grant-date
fair value of the award and the estimated number of awards that are expected to vest. That cost
will be recognized over the period during which an employee is required to provide service in
exchange for the award, which is usually the vesting period. SFAS 123R supersedes APB 25, which
the Company had previously elected to follow. SFAS 123R will be effective for the Company at the
beginning of the fiscal first quarter of 2006. SFAS 123R applies to all awards granted after the
required effective date and to awards modified, repurchased, or canceled after that date.
Compensation cost is recognized on or after the required effective date for the portion of
outstanding awards for which the requisite service has not yet been rendered, based on the
grant-date fair value of those awards calculated under SFAS 123 that the Company has followed for
disclosure purposes. For periods before the required effective date, the Company may elect to
adjust financial statements of prior periods on a basis consistent with the pro forma disclosures
required for those periods by SFAS 123. The Company has elected not to restate prior 7




---



##### Table of Contents



periods. Based on stock options granted through March 31, 2005, the Company estimates that it
will record additional costs relating to compensation expense as a result of the adoption of SFAS
123R starting in the first quarter of 2006. 
 ITEM 2: MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis should be read in conjunction with our consolidated
financial statements and related notes included in Item 1 of Part I of this quarterly report and
the audited consolidated financial statements and notes and Managements Discussion and Analysis of
Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the
year ended December 31, 2004. Company Overview We provide an enterprise-level information technology solution for the clinical analysis and
management of digital medical images within health care provider organizations. Our solution
consists of advanced visualization and image management software, third-party components and
comprehensive support services. Our web-enabled advanced visualization software, which is hosted
by the customer, provides physicians across the enterprise -in multiple medical specialties and at
any network access point -with tools to manipulate and analyze images in 2D and 3D. We enable
physicians to better understand internal anatomic structure and pathology, improving clinical
diagnoses, disease screening and therapy planning. We believe our solution improves physician
productivity and patient care, enhances customer revenue opportunities, automates complex medical
imaging workflow and helps to maximize our customers investment in capital equipment and clinical
information systems. Summary Our revenue for the quarter ended March 31, 2005 was $11.3 million, which represents a 59.3%
increase over the corresponding period in 2004. This increase was comprised of a 57.2% increase in
system sales revenue and a 63.8% increase in support services revenue. Our overall gross margin
percentage increased from 18.9% for the quarter ended March 31, 2004 to 30.3% for the quarter ended
March 31, 2005. We achieved gross margin percentages of 37.5% and 14.8% for system sales and
support services revenue, respectively, during the quarter ended March 31, 2005, compared to 28.9%
and (3.2%) for the corresponding period in 2004. We recorded a net loss for the quarter ended
March 31, 2005 of $4.8 million, compared with a net loss of $3.6 million for the corresponding
period in 2004. Also, during February 2005, we completed our initial public offering, selling a total of
5,750,000 shares of our common stock at a price of $13.00 per share, which resulted in net proceeds
to the Company of approximately $67.2 million. With a portion of the proceeds from the offering,
we repaid $4.0 million of our subordinated debt. We also recorded a non-cash interest charge of
$0.6 million for the write-off of the debt discount related to warrants issued in connection with
the subordinated debt. Critical Accounting Policies and Estimates Our consolidated financial statements are prepared in accordance with accounting principles
generally accepted in the United States. The preparation of these consolidated financial
statements requires us to make estimates and assumptions that affect the reported amounts of
assets, liabilities, revenue, costs and expenses and related disclosures. On an ongoing basis, we
evaluate our estimates and assumptions. Our actual results may differ from these estimates. We believe that of our significant accounting policies, which are described in Note 2 of the
notes to our consolidated financial statements included in our Annual Report on Form 10-K for the
year ended December 31, 2004, the following accounting policies involve a greater degree of
judgment and complexity. Accordingly, these are the policies we believe are the most critical to
aid in fully understanding and evaluating our consolidated financial condition and results of
operations. 8




---



##### Table of Contents



Revenue Recognition and Deferred Revenue We derive revenue from two primary sources: (1) system sales revenue, which includes software
license revenue and third-party component sales revenue and (2) support services revenue, which
includes fees related to implementation, training, software maintenance, ongoing customer support
and third-party component maintenance. While the basis for software license revenue recognition is
substantially governed by the provisions of AICPA Statement of Position 97-2, (SOP 97-2),
Software Revenue Recognition, as amended, in the application of this standard, we exercise judgment
and use estimates in connection with the determination of the amount of software license and
support services revenue to be recognized in each accounting period. We sell software under three types of licenses: (1) Perpetual licenses: software licensed on a perpetual basis to a customer based on a
fixed number of users and/or estimates of annual study volumes where the customer has no right
to return the licensed software. (2) Enterprise licenses: software licensed on a perpetual basis to a customer (typically a
multi-facility health care provider), as opposed to licensing based on a fixed number of users
or on estimates of annual study volumes, where the customer has no right to return the licensed
software. (3) Term licenses: software licensed for a specific period of time according to a fixed
number of users and/or estimates of annual study volumes. Generally, our software license arrangements do not include significant modification or
customization of the underlying software and, as a result, we recognize license revenue when: (1)
persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) customer payment is
deemed fixed or determinable and (4) collection is probable. We assess each of the four criteria
as follows:  
    Persuasive evidence of an arrangement exists:Before we recognize revenue, we conduct
an assessment to determine whether a binding arrangement exists with the customer
counterparty. To this end, it is our customary practice to have a written contract, which
is signed by both the customer and us, or a purchase order from those customers that have
previously negotiated a standard end-user license arrangement, prior to recognizing revenue
on an arrangement.
    Delivery has occurred:Before we recognize revenue under any arrangement, we determine
whether our software has been actually delivered to the customer counterparty. It is our
customary practice to obtain formal acceptance for our software, which is evidenced by
written customer acknowledgement. In the event that we grant a customer the right to
specified upgrades, we defer recognition of the entire arrangement fee until we deliver the
specified upgrades as we have not established vendor-specific objective evidence (VSOE) of
fair value for specified upgrades. Specified upgrades include, but are not limited to,
future software deliverables that are stated in the customer contract.
    The customers payment is deemed fixed or determinable:If we find that an arrangement
exists and that delivery has occurred, before we recognize revenue in respect of any
particular customer, we assess whether fees are fixed or determinable and free of
contingencies or significant uncertainties at the time of sale and recognize revenue when
all other applicable revenue recognition requirements are met. While our standard payment
terms are net 30 days, we have, on a few occasions, extended payment terms beyond 30 days
(but none greater than six months) to creditworthy customers. We have established a
successful history of collection, without concessions, on these receivables; therefore
satisfying the required criteria for revenue recognition. If the fee is determined not to
be fixed or determinable, we recognize revenue as the amounts become due and payable.
    Collection is probable:In addition to the three foregoing factors which we review for
each customer arrangement, before we recognize any revenue for any particular customer, we
also conduct an assessment of the likelihood of collection from that customer. Both new
and existing customers are subjected to a credit review that evaluates such customers
financial position and ultimately its ability to pay. For follow-on sales to existing
customers, prior payment history is also used to evaluate probability of collection. If it
is determined from the outset of the arrangement that collection is not probable based upon
our credit review 9




---



##### Table of Contents



process, revenue is recognized on a cash-collected basis if all other applicable revenue
recognition criteria are met. We account for software license and non-recurring support services revenue included in
multiple element arrangements using the residual method. Under the residual method, the fair value
of the undelivered elements (i.e., software maintenance and ongoing support services) based on VSOE
of fair value is deferred and the remaining portion of the arrangement fee is allocated to the
delivered elements (i.e., software license and non-recurring support services). If evidence of the
fair value of one or more of the undelivered services does not exist, revenue is deferred and
recognized when delivery of those services occurs or fair value can be established. We determine
VSOE of fair value for ongoing support services revenue based upon the renewal rates for the
maintenance and ongoing support, which coincide with our pricing model. Significant incremental
discounts offered in multiple element arrangements that would be characterized as separate elements
are infrequent and are allocated to software license revenue under the residual method. For term license arrangements, we recognize revenue for the multiple element arrangement over
the term of the arrangement beginning in the month after we receive customer acceptance, provided
that the other applicable revenue recognition criteria have been met. Software maintenance services generally include rights to upgrades (when and if available),
telephone support, updates and bug fixes. Software maintenance revenue is recognized ratably over
the term of the maintenance contract on a straight-line basis when all of the applicable revenue
recognition requirements are met. We include the first year of software maintenance in the
software license fee. We defer this software maintenance fee based on its fair value and recognize
it ratably over the first year of the arrangement. Ongoing support services generally include telephone support related to third-party components
as well as quarterly customer metric reporting and other services. Ongoing support service revenue
is recognized ratably over the term of the ongoing support services contract on a straight-line
basis when all of the applicable revenue recognition requirements are met. We recognize revenue related to the third-party components according to guidance set forth in
Emerging Issues Task Force Issue No. 00-21, Accounting for Revenue Arrangements with Multiple
Deliverables(EITF 00-21). Third-party component revenue, including hardware sales and hardware
maintenance, is recognized in accordance with contractual terms. When we are responsible for
installing the third-party components, revenue is recognized when the third-party components are
delivered, installed and accepted by the customer. When we are not responsible for installing the
third-party components, revenue is recognized when the third-party components are delivered to the
customer. We qualify to recognize hardware sales and hardware maintenance under EITF 00-21 as a
result of the following factors: (1) our software is not essential to the functionality of the
hardware, (2) our customers have the ability to purchase the hardware from other vendors and (3)
the purchase price of the hardware and hardware maintenance is separately stated in our contracts. The following is a summary of our product warranty and guarantee and our related accounting
policies for these agreements: (1) Our sales agreements with customers generally contain infringement indemnity provisions.
Under these agreements, we agree to indemnify, defend and hold harmless the customer in connection
with patent, copyright or trade secret infringement claims made by third parties with respect to
the customers authorized use of our products and services. The indemnity provisions generally
provide for our control of any required defense and settlement and cover costs and damages finally
awarded against the customer. Our infringement indemnity provisions typically give us the option
to make modifications of the product so it is no longer infringing or, if it cannot be corrected,
to require the customer to return the product in exchange for a specified payment for loss of use.
Our sales agreements with customers sometimes also contain indemnity provisions for death, personal
injury or property damage caused by our personnel or contractors in the course of performing
services to customers. Under these agreements, we agree to indemnify, defend and hold harmless the
customer in connection with death, personal injury and property damage claims made by third parties
with respect to actions of our personnel or contractors. The indemnity provisions generally
provide for our control of any required defense and settlement and cover costs and damages finally
awarded against the customer. The indemnity obligations contained in sales agreements generally
have no 10




---



##### Table of Contents



specified expiration date but typically limit the amount of award covered to some portion of
the fees paid by the customer over some portion of the contract term. To date, we have not
incurred costs to settle claims or pay awards under these indemnification obligations.
Accordingly, we have no liabilities recorded for these provisions as of March 31, 2005. (2) We warrant that our software products will perform in all material respects in accordance
with our standard published specifications in effect at the time of delivery of the licensed
products to the customer as long as the contract remains in effect. Additionally, we warrant that
our services will be performed by qualified personnel in a manner consistent with normally accepted
industry standards. If necessary, we would provide for the estimated cost of product and service
warranties based on specific warranty claims and claim history. However, we have not incurred
significant recurring expense under our product or service warranties. Accordingly, we have no
liabilities recorded for these provisions as of March 31, 2005. (3) Our standard contracts with customers typically provide for a 99% guarantee of system
availability and a 98% guarantee of component availability with penalty provisions if our solution
fails to meet the guarantee thresholds. Our 99% system availability guarantee covers our solution
as a whole, while the component guarantee covers each individual component, as in certain
circumstances a component may fail without affecting system availability. The penalty provisions
in our contracts typically allow for a reduction in the software maintenance fee related to failure
to meet guaranteed uptime percentages. We calculate these penalties as a percentage of the
software maintenance fee and would reduce the amount of the software maintenance fee charged in a
specific period for these penalties. To date, we have not incurred any penalties associated with
these guarantees. Accordingly, we have no liabilities recorded for these provisions as of March
31, 2005. Billings may not coincide with the recognition of revenue. Unbilled revenue occurs when
revenue recognition precedes billing to the customer, and arises primarily from sales with
predetermined billing schedules. Billings in excess of sales (deferred revenue) occur when billing
to the customer precedes revenue recognition, and arise primarily from sales with partial
prepayments upon contract execution and from maintenance revenue billed in advance of performance
of the maintenance activity. At March 31, 2005, approximately $4.7 million of the balance in
current deferred revenue is related to three contracts where we have deferred all contract revenue
accounted for under SOP 97-2 as a result of specified upgrades. The remaining balance in deferred
revenue is primarily a result of timing of differences in contract execution and acceptance. The
majority of our current deferred revenue relates to system sales and non-recurring services, such
as implementation and training. Deferred revenue is recognized upon delivery of our products, as
ongoing services are rendered or as other requirements requiring deferral under SOP 97-2 are
satisfied. The timing of customer acceptances could significantly affect the results of operations during
a given period. As noted above, we generally require written acknowledgement from the customer to
evidence that delivery of the products or services has occurred. Delays in the implementation
process could negatively affect operations in a given period by increasing volatility in revenue
recognition. Capitalization of Software Development Costs Research and development costs are charged to expense as incurred. However, the costs
incurred for the development of software that will be sold, leased or otherwise marketed are
capitalized when technological feasibility has been established and capitalization ceases when the
software is generally available for release. Judgment is involved in determining when
technological feasibility is reached. We believe that technological feasibility is reached when we
have completed a working model that is ready to be beta-tested at a customer site. These
capitalized costs are subject to an ongoing assessment of recoverability based on anticipated
future revenue and changes in technologies. Costs that are capitalized primarily consist of direct
labor. Amortization of capitalized software development costs begins when the product is available
for general release. Amortization is provided on a product-by-product basis using the
straight-line method over periods not exceeding two years. Unamortized capitalized software
development costs determined to be in excess of net realizable values are expensed immediately.
Historically, we have had very short periods of time between when we believe a product has reached
technological feasibility and the date on which we typically release our products for general
release. As a result, we have not capitalized material software development costs. 11




---



##### Table of Contents



Intangible and Other Long-Lived Assets In June 2001, the Financial Accounting Standards Board issued Statement No. 141 (SFAS No.
141) and SFAS No. 142. SFAS No. 141 requires the purchase method of accounting for all business
combinations after June 30, 2001, and that certain acquired intangible assets in a business
combination be recognized as assets separate from goodwill. We have applied SFAS No. 141 in our
allocation of the purchase price of the Ultravisual Medical Systems Corporation (Ultravisual)
merger, which occurred in May 2003. Accordingly, we have identified and allocated a value to the
intangibles based on discounted cash flow analyses and market research, as well as our judgment.
SFAS No. 142 requires that intangibles determined to have an indefinite life are not to be
amortized but are to be tested for impairment at least annually. We will evaluate intangible
assets for impairment on an annual basis and when impairment indicators are identified. In
assessing the recoverability of intangibles, we must make assumptions regarding estimated future
cash flows and other factors to determine the fair value of the respective assets. These estimates
include forecasted revenue, which is inherently difficult to predict. If these estimates or their
related assumptions change in the future, we may be required to record impairment charges for these
assets. Historically, intangible assets are reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable. Property,
equipment and intangible assets are amortized over their useful lives. Useful lives of the
intangible assets are based on managements estimates of the period that such assets will generate
revenue. Change in Financial Position As noted above, we completed our initial public offering during February 2005. The following
significant changes in our financial position occurred as a result of the completion of the initial
public offering:  
    We issued 10,827,403 shares of common stock upon the automatic conversion of
outstanding shares of preferred stock into shares of common stock.
    We issued 5,750,000 shares of common stock in connection with the initial public
offering.
    We issued 537,082 shares of common stock upon exercise of mandatorily redeemable
warrants in conjunction with the initial public offering.
    We received total cash proceeds from the initial public offering (net of
underwriting discount and offering expenses) of $67.2 million.
    With a portion of the proceeds from the offering, we repaid $4.0 million of our
subordinated debt.
    We invested the remaining proceeds from the offering in cash equivalents and
short-term investments. As of March 31, 2005, we have 20,203,378 shares of common stock issued, 20,027,621 shares of
common stock outstanding and warrants to purchase 57,114 shares of common stock outstanding at
exercise prices ranging from $1.65 to $5.52 per share. As of the close of the initial public
offering, we had no remaining warrants to purchase preferred stock outstanding. Results of Operations The following tables set forth information from our unaudited Consolidated Statements of
Operations for the quarters ended March 31, 2005 and 2004. The first table sets forth the
unaudited Consolidated Statements of Operations with accompanying calculations of the variances
from quarter to quarter, in dollars and on a percentage basis for each line item. The second table
presents information expressed as a percentage of total revenue except for cost of revenue related
to system sales and support services, which are expressed as a percentage of system sales and
support services revenue, respectively. Explanations of the reported variances from period to
period are contained in the paragraphs following the tables. 12




---



##### Table of Contents



Quarter EndedMarch 31,
    
    
    Variances2005
    
    
    2004
    
    
    $
    
    
    %(Dollars in thousands)Revenue:System sales
    
    $
    7,719
    
    
    $
    4,909
    
    
    $
    2,810
    
    
    
    57.2
    %Support services
    
    
    3,617
    
    
    
    2,208
    
    
    
    1,409
    
    
    
    63.8Total revenue
    
    
    11,336
    
    
    
    7,117
    
    
    
    4,219
    
    
    
    59.3Cost of revenue:System sales
    
    
    4,823
    
    
    
    3,489
    
    
    
    1,334
    
    
    
    38.2Support services
    
    
    3,083
    
    
    
    2,279
    
    
    
    804
    
    
    
    35.3Total cost of revenue
    
    
    7,906
    
    
    
    5,768
    
    
    
    2,138
    
    
    
    37.1Gross profit
    
    
    3,430
    
    
    
    1,349
    
    
    
    2,081
    
    
    
    154.3Operating expenses:Research and development
    
    
    2,385
    
    
    
    1,269
    
    
    
    1,116
    
    
    
    87.9Sales and marketing
    
    
    2,689
    
    
    
    1,738
    
    
    
    951
    
    
    
    54.7General and administrative
    
    
    2,555
    
    
    
    1,742
    
    
    
    813
    
    
    
    46.7Total operating expenses
    
    
    7,629
    
    
    
    4,749
    
    
    
    2,880
    
    
    
    60.6Operating loss
    
    
    (4,199
    )
    
    
    (3,400
    )
    
    
    (799
    )
    
    
    23.5Other income (expense):Interest income
    
    
    233
    
    
    
    2
    
    
    
    231
    
    
    NMInterest expense
    
    
    (852
    )
    
    
    (194
    )
    
    
    (658
    )
    
    
    339.2Total other income
(expense)
    
    
    (619
    )
    
    
    (192
    )
    
    
    (427
    )
    
    
    222.4Net loss
    
    $
    (4,818
    )
    
    $
    (3,592
    )
    
    $
    (1,226
    )
    
    
    34.1
 Quarter EndedMarch 31,2005
    
    
    2004Revenue:System sales
    
    
    68.1
    %
    
    
    69.0
    %Support services
    
    
    31.9
    
    
    
    31.0Total revenue
    
    
    100.0
    
    
    
    100.0Cost of revenue:System sales
    
    
    62.5
    
    
    
    71.1Support services
    
    
    85.2
    
    
    
    103.2Total cost of revenue
    
    
    69.7
    
    
    
    81.1Gross profit
    
    
    30.3
    
    
    
    18.9Operating expenses:Research and development
    
    
    21.0
    
    
    
    17.8Sales and marketing
    
    
    23.7
    
    
    
    24.4General and administrative
    
    
    22.6
    
    
    
    24.5Total operating expenses
    
    
    67.3
    
    
    
    66.7Operating loss
    
    
    (37.0
    )
    
    
    (47.8
    )Other income (expense):Interest income
    
    
    2.0
    
    
    
    0.0Interest expense
    
    
    (7.5
    )
    
    
    (2.7
    )Total other income
(expense)
    
    
    (5.5
    )
    
    
    (2.7
    )Net loss
    
    
    (42.5
    )%
    
    
    (50.5
    )%
 Revenue Total revenue, consisting of system sales and support services, increased by $4.2 million, or
59.3%. The increase in revenue was attributable to an increase in the size and number of new
customer installations as well as more of our system installations being perpetual licenses rather
than term licenses. During the quarters ended March 13




---



##### Table of Contents



31, 2004 and 2005, we recognized initial system sales revenue related to four and 13 customer
contracts, respectively. All contracts for which initial system sales revenue was recognized
during the quarters ended March 31, 2004 and 2005 were perpetual software licenses. We believe that the increased number of our contracts was a result of increased customer
awareness and acceptance of our products and services with multi-facility healthcare providers.
This customer awareness and acceptance was largely attributable to our marketing activities
associated with these providers, which included up-front research on prospects, increased responses
to Requests for Proposals and marketing campaigns, such as programs and exhibits at major trade
shows, specifically targeting multi-facility health care providers. We expect revenue to continue
to increase as we recognize revenue from our existing long-term customer agreements while also
recognizing revenue related to new customer agreements. System sales revenue increased by $2.8 million, or 57.2%. Approximately $1.4 million of the
increase was attributable to more health care institutions buying and installing our solution, and
approximately $1.4 million of the increase is related to a shift in our sales from primarily term
licenses, in which revenue is recognized ratably over the multiple years covered by the licenses,
to primarily perpetual licenses, in which revenue for the license fee is recognized at system
acceptance assuming all applicable revenue recognition criteria have been satisfied. Support services revenue increased by $1.4 million, or 63.8%. Approximately $0.9 million of
the increase in support services revenue was attributable to a larger number of customers that have
implemented our solution and are paying us ongoing support and maintenance fees. The remaining
$0.5 million increase in support services revenue was related to the increase in the recognition of
non-recurring revenue related to services such as implementation and training for these new
customers. Cost of Revenue Cost of revenue increased by $2.1 million, or 37.1%. This increase was attributable to
increased purchases of third-party components as a result of the increased number and size of new
customer installations. Cost of revenue as a percentage of total revenue decreased from 81.1% for
the quarter ended March 31, 2004 to 69.7% for the quarter ended March 31, 2005. The decrease in
cost of revenue as a percentage of total revenue was a result of increased software license revenue
as a portion of total revenue as a result of our continued transition to selling perpetual software
licenses. Our costs associated with software licenses as a percentage of total revenue were
significantly lower than costs associated with other components of our revenue. Cost of system sales increased by $1.3 million, or 38.2%. This increase was caused by the
larger number of health care institutions that acquired and installed our solution. Cost of system
sales as a percentage of system sales revenue decreased from 71.1% for the quarter ended March 31,
2004 to 62.5% for the quarter ended March 31, 2005. We anticipate that our cost of revenue will
continue to increase in absolute dollars as a result of additional purchases of third-party
components related to customer installations. Cost of support services increased by $0.8 million, or 35.3%. This increase was caused by an
increase in staffing levels in our support services teams. Cost of support services as a
percentage of support services revenue decreased from 103.2% for the quarter ended March 31, 2004
to 85.2% for the quarter ended March 31, 2005. The decrease in cost of support services as a
percentage of total support services revenue was a result of efficiencies realized as our customer
base grew and the cost of support services was spread over the broader base of customers.
Additionally, in early 2004, we acquired software that enabled some of our previously manual
methods of providing support to be automated, thereby lowering the cost of service delivery. Gross Margin Percentage Our gross margin percentage increased from 18.9% of total revenue for the quarter ended March
31, 2004 to 30.3% of total revenue for the quarter ended March 31, 2005 primarily as a result of
the increased revenue attributable to software licenses that have a higher margin than other
components of our revenue. 14




---



##### Table of Contents



Research and Development Research and development expenses increased by $1.1 million, or 87.9%. This increase is
attributable to an increase in the number of personnel, which accounted for approximately $0.6
million of the increase, as well as increased spending for outside consultants, which accounted for
approximately $0.2 million of the increase. Research and development headcount increased to 63
employees at March 31, 2005 from 49 employees at January 1, 2004. In the future, we expect to
continue to invest in research and development as we continue to improve our existing technology
and expand our software offering. Sales and Marketing Sales and marketing expenses increased by $1.0 million, or 54.7%. This increase was
attributable to increases in personnel-related and commission expenses as a result of an increase
in the number of sales representatives, sales support and marketing personnel, the signing of
additional contracts and expansion of our marketing efforts, including targeted campaigns related
to multi-facility health care providers. Sales and marketing headcount increased to 38 employees
at March 31, 2005 from 29 employees at January 1, 2004. As a result, personnel expenses increased
approximately $0.4 million, in addition to an increase in commission expense of approximately $0.4
million. Sales and marketing expenses as a percentage of total revenue remained relatively
consistent (24.4% for the quarter ended March 31, 2004 as compared to 23.7% for the quarter ended
March 31, 2005). We expect to increase our sales and marketing expenses as we hire additional
sales and marketing personnel and focus on increasing market awareness of our products and service
offerings. General and Administrative General and administrative expenses increased by $0.8 million, or 46.7%. This increase was
attributable to an increase in personnel related expenses of approximately $0.2 million from
January 1, 2004 to March 31, 2005, as well as increased expenses related to insurance and
professional services, such as accounting and legal, of approximately $0.2 million and increased
stock-based compensation expense of approximately $0.3 million. General and administrative
expenses as a percentage of total revenue decreased from 24.5% for the quarter ended March 31, 2004
to 22.6% for the quarter ended March 31, 2005, which is primarily a factor of our rapid revenue
growth. We expect our general and administrative expenses to continue to increase in absolute
dollars as a result of being a public company. Specifically, we expect to incur increased costs
associated with accounting, consulting, legal and other professional services, increased insurance
costs and increased personnel in our finance and legal functions. Operating Loss Operating loss increased by $0.8 million, or 23.5%. Operating loss as a percentage of total
revenue decreased from 47.8% for the quarter ended March 31, 2004 to 37.0% for the quarter ended
March 31, 2005 as a result of the total revenue increase of $4.2 million coupled with the increased
leverage in operating costs discussed above. Interest Income Interest income increased by $0.2 million. This increase is a result of investing the
proceeds from our initial public offering. Interest expense increased by $0.7 million, or 339.2%. During the quarter ended March 31,
2005, we used a portion of the proceeds from our initial public offering to repay $4.0 million of
our subordinated debt. In conjunction with this extinguishment, we recorded a non-cash interest
charge of $0.6 million for the write-off of the subordinated debt discount related to warrants
issued in connection with the subordinated debt. Liquidity and Capital Resources As of March 31, 2005, we had $70.2 million in cash, cash equivalents and marketable
securities, working capital of $49.8 million and $5.5 million of borrowings, as compared to $6.0
million of cash and cash equivalents, working capital deficit of $9.4 million and $9.5 million of
borrowings as of December 31, 2004. As of March 31, 2005 and 15




---



##### Table of Contents



December 31, 2004, we had approximately $0.5 million and $0.8 million, respectively, of
restricted cash and cash equivalents held as collateral for equipment loans related to customer
third-party components and one internal equipment lease. During the quarter ended March 31, 2005,
the restrictions related to one of the equipment loans were satisfied and therefore we reclassified
the amount of $0.4 million to unrestricted cash. The remaining restrictions on the cash will be
released in connection with the maturity of the remaining equipment loan and the expiration of the
lease. Operating Activities During the three months ended March 31, 2005, cash provided by operations was $1.8 million,
which consisted of an increase of $4.3 million from changes in working capital accounts and $2.5
million of cash used resulting from our net loss offset by non-cash items. Changes in the working
capital accounts primarily related to a decrease in trade accounts receivable and an increase in
deferred revenue due to an increased customer base. There was also an increase in accounts payable
that was offset by a decrease in accrued expenses. In addition, we have accounted for a decrease
of $1.3 million in certain prepaid assets during the period as cash flow from financing activities
because these prepaid assets related to our anticipated initial public offering. If we had not
completed our initial public offering, this decrease would have been accounted for as cash flow
from operating activities. Our days sales outstanding on an annualized basis as of March 31,
2004, December 31, 2004 and March 31, 2005 were 74 days, 114 days and 88 days, respectively. Our
weighted average collection period as of March 31, 2005 was 60 days compared to 55 days at December
31, 2004. The changes in other working capital accounts were primarily driven by increased
operations and the timing of cash payments. During the three months ended March 31, 2004, cash provided by operations was $0.4 million,
which consisted of an increase of $2.6 million from changes in working capital accounts and $2.2
million of cash used in operations. Changes in the working capital accounts primarily related to a
decrease in trade accounts receivable and an increase in deferred revenue due to an increased
customer base and timing of customer payments. The changes in other working capital accounts were
primarily driven by increased operations and the timing of cash payments. Cash provided by and used in operating activities has historically been affected by changes in
working capital accounts, primarily deferred revenue, accounts receivable and accrued expenses.
Fluctuations within accounts receivable and deferred revenue are primarily related to the timing of
billings and the associated revenue recognition. Investing Activities We used cash of $32.4 million and $0.3 million for investing activities during the first three
months of 2005 and 2004, respectively. We used $2.7 million and $0.3 million for property and equipment purchases during the first
three months of 2005 and 2004, respectively. Approximately $2.0 million of the purchases for the
first quarter of 2005 related to investments in equipment for internal use, including test
equipment for our research and development and quality assurance departments as well as computer
equipment for new and existing personnel. Substantially all of the purchases for the first quarter
of 2004 related to computer equipment for new and existing personnel. We anticipate that we will
continue to purchase property and equipment as necessary in the normal course of business.
Approximately $0.7 million of the purchases for the first quarter of 2005 related to investments in
equipment located at contracted customer sites. We anticipate that we will incur additional
capital expenditures at customer sites as we further standardize and update our equipment platform. We used $29.6 million for the purchase of marketable securities during the first three months
of 2005. The marketable securities consist of U.S. government agency obligations and corporate
commercial paper, all with maturities of less than one year. Financing Activities Cash provided by (used in) financing activities totaled $65.2 million and $(0.7) million for
the three months ended March 31, 2005 and 2004, respectively. The cash provided by financing
activities for the first three months 16




---



##### Table of Contents



of 2005 resulted primarily from the completion of our initial public offering. This inflow of
cash was offset by our $4.0 million repayment of our subordinated debt and other payments on
borrowings. During the three months ended March 31, 2005, we also had $0.4 million of restricted
cash released from restriction. The cash used in financing activities for the first three months
of 2004 resulted from payments on existing borrowings and an addition to restricted cash used to
secure a letter of credit for an operating lease. The following table summarizes, as of March 31, 2005, the general timing of future payments
under our outstanding loan agreements, lease agreements and other long-term contractual
obligations: Payments Due by PeriodLess than 1
    
    
    
    
    
    
    
    
    
    
    More Than 5Contractual Cash Obligations
    
    Total
    
    
    Year
    
    
    1-3 Years
    
    
    3-5 Years
    
    
    Years(Dollars in thousands)Long-term debt
    
    $
    4,579
    
    
    $
    2,181
    
    
    $
    2,398
    
    
    $
    
    
    
    $
    Capital lease obligations
    
    
    1,545
    
    
    
    782
    
    
    
    763
    
    
    
    
    
    
    
    Operating leases
    
    
    3,203
    
    
    
    809
    
    
    
    1,167
    
    
    
    1,227
    
    
    
    Total contractual cash obligations
    
    $
    9,327
    
    
    $
    3,772
    
    
    $
    4,328
    
    
    $
    1,227
    
    
    $
    
 In April 2004, we entered into a loan and security agreement with a bank under which we can
borrow up to $4.0 million subject to certain restrictions. Interest accrues at the prime rate plus
1.5% to 2.0%, depending on our net income. This line of credit was amended as of July 31, 2004 and
expires April 30, 2006 at which time all advances will be due and payable. As of March 31, 2005 we
had no outstanding balance under this line of credit. We believe our existing cash, together with future cash flows from operations and the
availability under our loan and security agreement will be sufficient to execute our business plan
in 2005. However, any projections of future cash inflows and outflows are subject to uncertainty.
Our future capital requirements will depend on many factors, including our rate of revenue growth,
the expansion of our marketing and sales activities, the timing and extent of spending to support
product development efforts and expansion into new territories, the timing of introductions of new
products and services and enhancements to existing products and services, and the continuing market
acceptance of our solution. To the extent that our existing cash, together with future cash flows
from operations and the availability under our loan and security agreement are insufficient to fund
our future activities, we may need to raise additional funds through equity or debt financing.
Although we are currently not a party to any binding agreement or letter of intent with respect to
potential investments in, or acquisitions of, complementary businesses, services or technologies,
we may enter into these types of arrangements in the future, which could also require us to seek
additional equity or debt financing. Additional funds may not be available on terms favorable to
us or at all. Recently Issued Accounting Pronouncements In December 2004, the FASB issued Statement No. 123 (revised 2004), Share-Based Payment
(SFAS 123R). SFAS 123R establishes standards for the accounting for transactions in which an
entity exchanges its equity instruments for goods or services. It focuses primarily on accounting
for transactions in which an entity obtains employee services in share-based payment transactions.
SFAS 123R requires a public entity to measure the cost of employee services received in exchange
for an award of equity instruments based on the grant-date fair value of the award and the
estimated number of awards that are expected to vest. That cost will be recognized over the period
during which an employee is required to provide service in exchange for the award, which is usually
the vesting period. SFAS 123R supersedes APB 25, which the Company has elected to follow. SFAS
123R will be effective for the Company at the beginning of the fiscal first quarter of 2006. SFAS
123R applies to all awards granted after the required effective date and to awards modified,
repurchased, or canceled after that date. Compensation cost is recognized on or after the required
effective date for the portion of outstanding awards for which the requisite service has not yet
been rendered, based on the grant-date fair value of those awards calculated under SFAS 123 that
the Company has followed for disclosure purposes. For periods before the required effective date,
the Company may elect to adjust financial statements of prior periods on a basis consistent with
the pro forma disclosures required for those periods by SFAS 123. The Company has elected not to
restate prior periods. Based on stock options granted through March 31, 2005, the Company
estimates that it will record additional costs relating to compensation expense as a result of the
adoption of SFAS 123R starting in the first quarter of 2006. 17




---



##### Table of Contents



Forward Looking Statements; Important Factors Affecting Future Results Some of the statements made in this section captioned Managements Discussion and
Analysis of Financial Condition and Results of Operations contain forward-looking statements which
reflect our plans, beliefs and current views with respect to, among other things, future events and
financial performance. We often identify these forward-looking statements by the use of
forward-looking words such as believe, expect, potential, continue, may, will,
should, could, would, seek, predict, intend, plan, estimate, anticipate or the
negative version of those words or other comparable words. Any forward-looking statements
contained in this Quarterly Report are based upon our historical performance and on current plans,
estimates and expectations. The inclusion of this forward-looking information should not be
regarded as a representation by us or any other person that the future plans, estimates or
expectations contemplated by us will be achieved. Such forward-looking statements are subject to
various risks and uncertainties. These risks, uncertainties and other factors include, among
others, the risk that we may not compete successfully against larger competitors, risks associated
with our history of operating losses, the risk that we may not manage our growth effectively, risks
associated with our reliance on continuing relationships with large customers, the risk of
significant product errors or product failures, our reliance on reseller arrangements for important
components of our solution, the risk that we may not respond effectively to changes in our
industry, our customers reliance on third party reimbursements, and the potential impact on our
business of FDA regulations and other applicable health care regulations. In addition, there are
or will be important factors that could cause our actual results to differ materially from those
indicated in these forward-looking statements. These cautionary statements should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included in this Quarterly Report and in
our 2004 Annual Report on Form 10-K. Moreover, we operate in a continually changing business
environment, and new risks and uncertainties emerge from time to time. Management cannot predict
these new risks or uncertainties, nor can it assess the impact, if any, that any such risks or
uncertainties may have on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ from those projected in any forward-looking statement.
Accordingly, the risks and uncertainties to which we are subject can be expected to change over
time, and we undertake no obligation to update publicly or review the risks or uncertainties
described herein. We also undertake no obligation to update publicly or review any of the
forward-looking statements made in this Quarterly Report, whether as a result of new information,
future developments or otherwise. If one or more of the risks or uncertainties referred to in this Quarterly Report or in our
2004 Annual Report on Form 10-K materialize, or if our underlying assumptions prove to be
incorrect, actual results may vary materially from what we projected. Any forward-looking
statements you read in this prospectus reflect our current views with respect to future events and
are subject to these and other risks, uncertainties and assumptions relating to our operations,
financial condition, growth strategy and liquidity. You should specifically consider the factors
identified in this Quarterly Report that could cause actual results to differ. For a more complete discussion of the important factors that may impact future performance and
prospects, please refer to the discussion of Risk Factors as set forth in our 2004 Annual Report on
Form 10-K in the portion of Item 7 labeled Managements Discussion and Analysis of Financial
Condition and Results of Operations  Risk Factors. 
 ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Our debt instruments do not expose us to material market risks relating to changes in interest
rates. Some of the proceeds of our initial public offering have been invested in short-term,
interest-bearing, investment grade securities pending their application. The value of these
securities will be subject to interest rate risk and could fall in value if interest rates rise. The primary objective of our investment activities is to preserve principal while maximizing
the income we receive from our investments without significantly increasing our risk. We invest
excess cash principally in U.S. marketable debt securities from a diversified portfolio of
institutions with strong credit ratings and in U.S. government and agency bills and notes, and by
policy, limit the amount of credit exposure at any one institution. 18




---



##### Table of Contents



These investments are generally not collateralized and mature within one year. Some of the
securities we invest in may have market risk. This means that a change in prevailing interest
rates may cause the fair value of the principal amount of the investment to fluctuate. To minimize
this risk, we schedule our investments to have maturities that coincide with our expected cash flow
needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we
believe we have no material exposure to interest rate risk arising from our investments.
Therefore, no quantitative tabular disclosure is provided. 
 ITEM 4: CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures Our management, with the participation of our chief executive officer and chief financial
officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2005. Based on this evaluation,
our chief executive officer and chief financial officer concluded that, as of March 31, 2005, our
disclosure controls and procedures were (1) designed to ensure that material information relating
to us is made known to our chief executive officer and chief financial officer by others within our
company, particularly during the period in which this report was being prepared and (2) effective,
in that they provide reasonable assurance that information required to be disclosed by us in the
reports that we file or submit under the Exchange Act is recorded, processed, summarized and
reported within the time periods specified in the Securities and Exchange Commissions rules and
forms. Changes in Internal Control over Financial Reporting No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended March 31, 2005 that has
materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting. 
 PART II: OTHER INFORMATION 
 ITEM 1: LEGAL PROCEEDINGS None 
 ITEM 2: UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Unregistered Sales of Equity Securities As previously reported in our 8-K submitted on February 15, 2005, on February 14, 2005, and in
connection with the Companys Public Offering, holders of certain warrants to purchase shares of
Common Stock were required by the terms of their warrants to exercise such warrants. Some of these
elected to exercise their warrants by paying cash for the exercise price. In connection with these
exercises, the Company issued 141,217 shares of Common Stock and received $735,718.64 upon exercise
and no underwriting discounts or commissions were paid. Other holders of such warrants exercised
their warrants on a cashless basis by surrendering their right to purchase a portion of the shares
of Common Stock based on a deemed value of $13.00 per share, representing the price of the Common
Stock to the public in the Public Offering. In connection with the cashless exercise of warrants,
these warrants were surrendered and the Company issued 395,865 shares of Common Stock upon
exercise, and no underwriting discounts or commissions were paid. The Company offered and sold the Common Stock issued in connection with the cashless exercise
of warrants in reliance on the exemption from registration for exchanges of securities with
existing security holders by virtue of Section 3(a)(9) of the Securities Act of 1933, as amended.
The Company offered and sold the Common Stock upon the cash exercise of warrants in reliance on the
exemption from registration for offers and sales of securities that do not involve a public
offering by virtue of Section 4(2) of the Securities Act of 1933, as amended. 19




---



##### Table of Contents



On January 10, 2005, we issued 12,755 shares of our common stock and 12,370 shares of our
Series D Preferred Stock to a warrant holder pursuant to the exercise of the warrant held by such
warrant holder. On February 28, 2005, we issued 7,389 shares of our common stock to a warrant
holder pursuant to the exercise of the warrant held by such warrant holder. The Company offered
and sold the Common Stock upon the exercises of these warrants in reliance on the exemption from
registration for offers and sales of securities that do not involve a public offering by virtue of
Section 4(2) of the Securities Act of 1933, as amended. Since January 1, 2005, we have granted stock options to purchase 182,757 shares of common
stock with exercise prices ranging from $7.17 to $14.90 per share, to employees and directors
pursuant to our stock option plans. During the same period, we issued an aggregate of 200 shares
of our common stock pursuant to the exercise of a stock option issued pursuant to our stock option
plans. We claimed exemption from registration under the Securities Act for the sales and issuances
of all such securities other than the stock options granted to our directors under Rule 701
promulgated under the Securities Act in that such sales and issuances were made either pursuant to
written compensatory plans or pursuant to a written contract relating to compensation, as provided
by Rule 701. The stock options granted to our directors were exempt from registration pursuant to
Section 4(2) of the Securities Act of 1933, as amended, as they were issued in a transaction not
involving public offering. Use of Proceeds from Initial Public Offering Our initial public offering of common stock was effected through a Registration Statement on
Form S-1 (File No. 333-120621) that was declared effective by the Securities and Exchange
Commission on February 8, 2005, pursuant to which we sold all 5,750,000 shares of our common stock
registered. We received net proceeds of approximately $67.2 million from the offering. We used
$4.0 million of the net proceeds to repay borrowings outstanding under our subordinated notes on
February 18, 2005. We invested the remaining net proceeds, after payment of the subordinated notes
referred to in the preceding paragraph, in short-term, investment-grade, interest bearing
instruments. In addition, during the first quarter of 2005, we spent approximately $2.7 million on capital
purchases, substantially all of which was spent on purchases of equipment. 
 ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS In connection with our preparations for our initial public offering, stockholder consents were
sought for a number of actions pursuant to Section 228 of the Delaware General Corporation Law. We
solicited consent for the following matters:  
    Action 1. Approval of an amendment to Emageons Amended and Restated
Certificate of Incorporation to effect a reverse stock split, at a ratio of
one-for-eight and one-quarter, of all of the issued and outstanding shares of the
Companys Common Stock;
    Action 2. Adoption of an Amended and Restated Certificate of Incorporation;
    Action 3. Adoption of Amended and Restated Bylaws;
    Action 4. Election of Chris H. Horgen as the director nominated by the
holders of the Series B and B-1 Preferred Stock, Fred C. Goad, Jr. and Hugh H.
Williamson, III as the directors nominated by the holders of the Series C Preferred
Stock, John W. Thompson as the director nominated by the holders of Series D
Preferred Stock, and Charles A. Jett, Jr., Arthur P. Beattie, Roddy J.H. Clark and
Mylle H. Mangum as the remaining at-large directors to our Board of Directors;
    Action 5. Classification of the above elected directors into classes with
one, two and three year terms upon the effectiveness of our Amended and Restated
Certificate of Incorporation referred to in Action 2;
    Action 6. Approval of the Emageon Inc. 2005 Equity Incentive Plan;
    Action 7. Approval of the Emageon Inc. 2005 Non-Employee Director Stock Incentive Plan;
    Action 8. Approval of the indemnification agreements to be entered into
between Emageon and its directors and officers; and 20




---



##### Table of Contents




    Action 9. Approval of the use of the initial public offering price as the
fair market value for shares of our common stock immediately prior to our initial
public offering for purposes of calculating fractional shares issuable in respect of
the reverse stock split. On February 4, 2005, the company had received a sufficient number of stockholder consents as
set forth in the table below to approve and make effective all such actions for which consent was
solicited. All Stockholders-
    
    
    
    All Stockholders-
    
    
    
    Preferred
    
    
    
    PreferredNumber of
    
    
    
    Percentage of
    
    
    
    Stockholders-
    
    
    
    Stockholders-Outstanding Shares
    
    
    
    Outstanding Shares
    
    
    
    Number of
    
    
    
    Percentage ofGranting Consent
    
    
    
    Granting Consent
    
    
    
    Outstanding Shares
    
    
    
    Outstanding SharesAction Number
    
    
    
    
    
    
    
    
    
    
    
    
    Granting Consent
    
    
    
    Granting ConsentAction 1
    
    
    
    96,699,388
    
    
    
    
    85.64
    %
    
    
    
    81,592,017
    (1)
    
    
    
    91.34
    %Action 2
    
    
    
    96,699,388
    
    
    
    
    85.64
    %
    
    
    
    81,592,017
    (1)
    
    
    
    91.34
    %Action 3
    
    
    
    96,699,388
    
    
    
    
    85.64
    %
    
    
    
    N/A
    
    
    
    
    N/AAction 4 (Series B
and B-1 Director)
(2)
    
    
    
    N/A
    
    
    
    
    N/A
    
    
    
    
    28,167,252
    
    
    
    
    100
    %Action 4 (Series C
Directors)
(2)
    
    
    
    N/A
    
    
    
    
    N/A
    
    
    
    
    23,190,681
    
    
    
    
    84.5
    %Action 4 (Series D
Director)
(2)
    
    
    
    N/A
    
    
    
    
    N/A
    
    
    
    
    10,608,031
    
    
    
    
    77.28
    %Action 4 (At-large
Directors)
    
    
    
    96,699,388
    
    
    
    
    85.64
    %
    
    
    
    N/A
    
    
    
    
    N/AAction 5
    
    
    
    96,699,388
    
    
    
    
    85.64
    %
    
    
    
    N/A
    
    
    
    
    N/AAction 6
    
    
    
    96,658,318
    
    
    
    
    85.60
    %
    
    
    
    N/A
    
    
    
    
    N/AAction 7
    
    
    
    96,658,318
    
    
    
    
    85.60
    %
    
    
    
    N/A
    
    
    
    
    N/AAction 8
    
    
    
    96,696,424
    
    
    
    
    85.60
    %
    
    
    
    81,592,017
    (1)
    
    
    
    91.34
    %Action 9
    
    
    
    N/A
    
    
    
    
    N/A
    
    
    
    
    75,686,667
    (3)
    
    
    
    90.79
    %
   (1)
    
    Includes Series A Preferred Stock, Includes Series B Preferred Stock, Series B-1
Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock,
voting together as a single class on an as-converted basis(2)
    
    Under the terms of the Stockholders Agreement (which terminated following our
initial public offering), certain directors were elected by a majority of the class of Preferred
Stock for which such director was elected(3)
    
    Includes Series B Preferred Stock, Series B-1 Preferred Stock, Series C Preferred
Stock, Series D Preferred Stock and Series E Preferred Stock, voting together as a single class on
an as-converted basis NOTE: Because the above consents were solicited prior to the completion of our public offering and
thus prior to the reverse stock split and the conversion of preferred stock into common stock, the
tally as set forth above is reported in pre-split and pre-conversion figures. 
 ITEM 6: EXHIBITS (a) Exhibit Index. Exhibit No.
    
    Description31.1
    
    Certification of Chief Executive Officer pursuant to
Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange
Act of 193431.2
    
    Certification of Chief Financial Officer pursuant to
Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange
Act of 1934
 21




---



##### Table of Contents



Exhibit No.
    
    Description32.1
    
    Certification of Chief Executive Officer and Chief Financial
Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 22




---



##### Table of Contents



SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized May 23,
2005. Emageon Inc.By:
    
    /s/ Charles A. Jett. Jr.Charles A. Jett, Jr.Chief Executive Officer(principal executive officer)By:
    
    /s/ W. Randall PittmanW. Randall PittmanChief Financial Officer and Treasurer(principal accounting and financial officer)
 23